LIVE LECTURE
Antibiotic Use in Diarrhoea
- July 14, 2025 | 19:30 AEST
- Add to calendar
Starts in
Days
Hours
Minutes
About the webinar
Gastrointestinal disease is a common reason for veterinary consultation although the vast majority of cases present only mild clinical signs. Even where the aetiology remains unknown, the prognosis in most cases is excellent. However, diarrhoea remains one of the most commonly-cited reasons for antimicrobial use in dogs and cats. Various studies have reported antibiotic prescription rates of 50-65% in dogs with acute diarrhoea with metronidazole the most frequently selected option. This talk will focus on the key drivers behind antibiotic-decision making, outline alternative therapeutic approaches and provide resources to educate all relevant stakeholders (colleagues and pet owners).
You will be able to join the live webinar directly from this page.
When is it?
Australia and New Zealand
USA and Canada
Other Countries
Australia and New Zealand
Date: Monday, 14 July 2025
Time: 19:30 AEST [Sydney] | 21:30 NZST [Auckland]
Time: 19:30 AEST [Sydney] | 21:30 NZST [Auckland]
USA and Canada
Date: Monday, 14 July 2025
Time: 05:30 EDT
Time: 05:30 EDT
Other Countries
All Countries are Invited to Join this Webinar! To check the time in your zone/country, please click here.
Note: This webinar is being recorded. If you are unable to attend the live lecture, a link to the recording will be shared with you a few days following the lecture.
Speaker

Dr Fergus Allerton
BSc BVSc CertSAM DipECVIM-CA MRCVS
Fergus graduated from the University of Bristol and completed a residency in Internal Medicine at the University of Liege, Belgium. He is a diplomate of the European College of Veterinary Medicine. Fergus is actively involved in veterinary antibiotic stewardship and contributed to the development of the PROTECT ME guidelines.
Within ENOVAT he is working on recommendations for antibiotic use for canine acute diarrhoea and surgical antimicrobial prophylaxis. He is the current editor of Companion and the BSAVA formulary and is also a member of the WSAVA Therapeutics Committee and a clinical medicine lead for RCVS Knowledge.